Research Paper Volume 13, Issue 5 pp 7096—7119
Berberine-induced TFEB deacetylation by SIRT1 promotes autophagy in peritoneal macrophages
- 1 Department of Pathophysiology, Key Laboratory of Cardiovascular Pathophysiology, Harbin Medical University, Harbin 150081, China
- 2 Yangpu Hospital, Tongji University, Shanghai 200090, China
- 3 Department of Pathophysiology, Harbin Medical University (Daqing), Daqing 163319, China
Received: June 4, 2020 Accepted: January 13, 2021 Published: February 26, 2021
https://doi.org/10.18632/aging.202566How to Cite
Copyright: © 2021 Zheng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Atherosclerosis is a chronic inflammatory disease that commonly affects the elderly and is characterized by vascular damage, macrophage infiltration, and plaque formation. Moreover, it increases the risk of cardiovascular disease. The pathogenesis of atherosclerosis involves an interplay between macrophage autophagy and apoptosis. A recently discovered transcription factor, transcription factor EB (TFEB) is known to activate autophagy in macrophages. Sirtuin deacetylase 1 (SIRT1), a nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylase, activates several transcription factors, including TFEB. We studied the effects of berberine on the NAD+ synthesis pathway and interactions between SIRT1 and TFEB. We also studied the effects of berberine-induced TFEB activation via SIRT1 on autophagy and apoptosis of peritoneal macrophages. We found that berberine promoted autophagy of peritoneal macrophages by activating SIRT1 via the NAD+ synthesis pathway and, in turn, promoting TFEB nuclear translocation and deacetylation. The functional regulation of SIRT1 and TFEB by berberine could be exploited as a potential therapeutic strategy for atherosclerosis.
Abbreviations
AS: atherosclerosis; SIRT1: sirtuin1; NAD+: nicotinamide adenine dinucleotide; TFEB: transcription factor EB; HAT: histone acetyl transferase; HDAC: histone deacetylase; IDO1: indole-2, 3-dioxygenase 1; QPRT: quinolinate phosphoribosyl transferase; NAMPT: nicotinamide phosphoribosyltransferase; NMNAT: nicotinamide/nicotinic acid mononucleotide adenylyltransferase; CVD: cardiovascular disease; NAM: nicotinamide; TSA: trichostatin A; 1MT: 1-methyl-L-tryptophan; PA: phthalic acid; IGF-1: insulin-like growth factor-1; Rapa: rapamycin; RT-qPCR: quantitative reverse transcription PCR; siRNA: small interfering RNA; 3-MA: 3-methyladenine; TEM: transmission electron microscopy; AO: acridine orange; AVOs: acidic vesicle organelles; MDC: monodansylcadaverine; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end-labeling; LC3β: microtubule-associated protein 1 light chain 3-β.